Survey Report for 101548

DEPARTMENT OF HEALTH AND HUMAN SERVICES		FORM APPROVED
CENTERS FOR MEDICARE & MEDICAID SERVICES		OMB NO. 0938-0391
STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	101548	A. BUILDING __________ B. WING ______________	07/14/2022
NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP
KINDRED HOSPICE	6161 BLUE LAGOON DR STE 170, MIAMI, FL, 33126
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.
Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other safeguards provide sufficient protection to the patients. (See reverse for further instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation
LABORATORY DIRECTOR’S OR PROVIDER/SUPPLIER REPRESENTATIVE’S SIGNATURE		TITLE	(X6) DATE
FORM CMS-2567 (02/99) Previous Versions Obsolete
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY SHOULD BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)
L0549
L0549	36646 Based on record reviews and interviews, the hospice failed to demonstrate that all drugs and treatment necessary for the palliation and management of terminal illness and related conditions in order to meet the needs of the patient were assessed and included in 1 out of 3 sample patients. (SP). SP #3. Findings include: Review of SP #3's Hospice Certification and Plan of Care, with a start of care of 6/8/2022, and Certification Period 6/8/2022 to 8/6/2022. A review of SP#3's medication list showed the following medications were approved by the hospice physician: Bumetanide, Elequis, Levofloxine, Quetiapine, Senna, Zolpiden, Montelucast. On 7/13/2022 at 2:30 PM, the Director of Clinical Services stated in the presence of Staff - A: " there was a miscommunication. The hospice nurse did not get all the information about all the patient's medications. The ALF did not provide all the lists of the medications that the patient had. The patient was just admitted from another ALF on June 8th." These findings were acknowledged by the Directors of Clinical Services, and the Quality Manager on 7/14/2022 at 12:30 PM.